<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255630</url>
  </required_header>
  <id_info>
    <org_study_id>H14-02788</org_study_id>
    <nct_id>NCT02255630</nct_id>
  </id_info>
  <brief_title>Anaerobic Power and Salbutamol</brief_title>
  <official_title>The Effects of High-dose Salbutamol on Anaerobic Cycling Power</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Natural Sciences and Engineering Research Council, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Athletes using inhaled β2-adrenoreceptor agonists (IBAs) win a disproportionate number of
      medals. However, most previous research has shown that β2 agonists do not improve exercise
      performance in either asthmatic or non-asthmatic athletes. Although the majority of these
      studies do not show an ergogenic effect, the small number of studies with extended exercise
      bouts (~60 minutes) do show an advantage. The investigators believe that a controlled yet
      sport-specific exercise protocol will elucidate this ergogenic effect. Because IBAs may have
      different effects on these two groups of athletes, the investigators will measure exercise
      performance in both female and male elite cyclists. The investigators hypothesize that
      athletes will perform better during a combination steady-state/sprint exercise task following
      salbutamol administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Power Output</measure>
    <time_frame>peak power output of the final 30 seconds of the cycling bout will be assessed.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ergogenic Athletic Performance</condition>
  <arm_group>
    <arm_group_label>Salbutamol inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will be exposed to 1600ug salbutamol 30min prior to exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will be exposed to 1600ug salbutamol 30min prior to exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cycling Exercise</intervention_name>
    <arm_group_label>Salbutamol inhalation</arm_group_label>
    <arm_group_label>Placebo inhalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  maximal oxygen consumption of ≥60 and ≥55 mL⋅kg-1⋅min-1 or ≥5⋅L⋅min-1 and ≥4⋅L⋅min-1
             for men and women

        Exclusion Criteria:

          -  pregnant women

          -  any history of uncontrolled respiratory or cardiac disease

          -  smokers

          -  diabetics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Koehle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of British Columbia, Environmental Physiology Laboratory</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>salbutamol</keyword>
  <keyword>exercise-induced bronchoconstriction</keyword>
  <keyword>anaerobic power</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

